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Summary  34	
    35	
Objective: Molecular epidemiology techniques in tuberculosis (TB) can identify high-36	
risk strains that are actively transmitted. We aimed to implement a novel strategy to 37	
optimize the identification and control of MDR-TB in a specific population. 38	
Methods: We developed a strain-specific-PCR tailored from whole-genome-39	
sequencing (WGS) data to track a specific multidrug-resistant prevalent strain in 40	
Equatorial Guinea (EG-MDR).  41	
Results: The PCR was applied prospectively on remnants of GeneXpert reaction 42	
mixtures owing to the lack of culture facilities in EG. In 147/158 cases (93%), we 43	
were able to differentiate between infection by the EG-MDR strain or by any other 44	
strain and found that 44% of all rifampicin resistant-TB cases were infected by EG-45	
MDR. We also analyzed 93 isolates obtained from EG 15 years ago, before MDR-TB 46	
had become the problem it is today. We found that 2 of the scarce historical MDR 47	
cases were infected by EG-MDR. WGS revealed low variability—6 SNPs acquired by 48	
this strain over 15 years—likely owing to the lack of a national program to treat 49	
MDR-TB. 50	
Conclusions: Our novel strategy, which integrated WGS analysis and strain-specific 51	
PCRs, represents a low-cost, rapid, and transferable strategy that allowed a 52	
prospective efficient survey and fast historical analysis of MDR-TB in a population.  53	
  54	
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Introduction    55	
 56	
Molecular epidemiology studies in tuberculosis (TB) are generally based on 57	
the universal application of a fingerprinting tool, mycobacterial interspersed repetitive 58	
units-variable number of tandem repeats (MIRU-VNTR), [1] to all the 59	
Mycobacterium tuberculosis (MTB) isolates in a population. MIRU-VNTR makes it 60	
possible to identify clusters of epidemiologically linked isolates and thus alerts to the 61	
existence of ongoing transmission chains that should be targeted by control measures.  62	
Once the most relevant ongoing transmission chains have been identified in a 63	
population, efforts can be prioritized to survey transmission hotspots and to track the 64	
transmission of the strains involved. In some cases, specific molecular tools have been 65	
developed to track selected strains [2‐7].  We proved the efficiency and flexibility of 66	
a new strategy based on strain-specific PCRs targeting specific SNPs identified from 67	
whole genome sequencing [8,	9].	68	
We sought a suitable scenario to further evaluate these novel surveillance 69	
strategies, specifically, a context where a single high-risk multidrug-resistant (MDR) 70	
strain could have a relevant role at the population level. We opted for Equatorial 71	
Guinea, a small, densely populated country in central Africa, recently revealed as a 72	
MDR hot-spot [10]. Indirect data point to the presence of a prevalent strain leading 73	
MDR transmission in this country. We found particularly relevant data [11]	 showing 74	
that all 10 Equatorial Guinean immigrants who arrived in Spain in different years and 75	
were residing in 6 different cities shared the same MDR strain, thus suggesting 76	
multiple independent importations of a highly prevalent MDR strain from the country 77	
of origin.  78	
In the present study, we go one step further in the application of novel 79	
strategies based on WGS. Our objectives were as follows: i) to evaluate the efficiency 80	
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of the strategy in the most relevant challenge that TB control offers today, namely, 81	
monitoring of transmission of multidrug resistance; and ii) to activate a fully 82	
comprehensive design that included both the prospective surveillance of transmission 83	
of MDR strains in a specific population and to perform a retrospective historical 84	







For the prospective study, we used the remnants of the mixtures of sputa with 91	
GeneXpert MTB/RIF Sample Reagent (Cepheid, Sunnyvale, CA, USA) used to 92	
perform GeneXpert tests in a study running between February 1st and April 30th 2015 93	
in Equatorial Guinea [10]. The study followed the standard ethical regulations. All 94	
smear-postive specimens from consecutive TB cases notified to the 2 main TB units 95	
in the country during the study period were collected. Sputa were mixed 1:2 with 96	
Sample Reagent and the reaction mixtures were stored at room temperature until 97	
delivery to our laboratory in Madrid, Spain. Deliveries were organized to ensure a 98	
maximum delay of 20 days between specimen collection in Equatorial Guinea and 99	
reception in our laboratory. 100	
 On arrival, mixtures were used to perform the GeneXpert assay. Three 101	
milliliters of the remaining mixture was used for DNA purification with a column-102	
based purification method (QIAamp DNA Mini Kit; Qiagen, Courtaboeuf, France) 103	
and eluted in 75 µl of buffer AE. We selected all the remnants from reaction mixtures 104	
in which GeneXpert detected MTB, 105	
 For the retrospective analysis, we took a 100-µl microliter aliquot from the 106	
isolates stored frozen at –70ºC, boiled it for 13 minutes, and centrifuged it at 13,000 107	






Whole genome sequencing 113	
 114	
WGS from 3 representative isolates was performed as indicated elsewhere 115	
[12]. We followed the standard library preparation protocol and used HiSeq 2000 116	
(GATC Biotech, Constance, Germany) and MiSeq (FISABIO, Valencia, Spain), 117	
which generated 51-300–bp paired-end reads. SNP analysis was performed following 118	
a workflow described elsewhere [12].   119	
Strain-specific SNPs were identified after comparing the SNPs extracted from 120	
WGS data with those from an in-house database of 219 strains representing the 121	
geographic and phylogenetic diversity of MTB complex [13]. We finally selected 122	
synonymous SNPs mapping in essential genes to be targeted in the ASO-PCR 123	
analysis to ensure their stability as genetic markers [14].  124	
 125	
Strain-specific ASO-PCR design 126	
 127	
We designed a multiplex ASO-PCR to target 4 SNPs  (Table)specific to the 128	
Equatorial Guinea MDR strain (EG-MDR strain), in order to rule out false negatives, 129	
as recommended elsewhere [15]. We designed 2 selective primers (SNP2 and SNP4) 130	
to target the alleles found in the surveyed strain, whereas the remaining 2 primers 131	
(SNP1 and SNP3) targeted the alleles from the non-surveyed strains (Table). Our 132	
design generated 2 different patterns depending on whether the strain tested was EG-133	
MDR or another strain.  134	
The assay conditions were 1.6 mM MgCl2, 1%DMSO, 0.8 µM of SNP1 135	
primers, 0.3 µM of SNP2 primers, 0.09 µM of SNP3 primers, 0.11 µM of SNP4 136	
primers, 200 µM dNTPs, and 0.4 µL AmpliTaq Gold (Applied Biosystems, Foster 137	
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City, California, USA). The PCR conditions were 95°C for 10 minutes followed by 138	





The isolates were genotyped using the MIRU-15 multiplex PCR [1] as 144	
described in Alonso et al. [16], but with 30 amplification cycles. The MIRU-VNTR 145	
loci order was as described elsewhere [11]. 146	
 147	
Susceptibility testing 148	
Susceptibility to isoniazid, rifampin, and second-line anti-TB drugs was 149	





Optimization of a strain-specific PCR for a prevalent Equatorial Guinean MDR 154	
strain 155	
 156	
 An immigrant who had recently arrived to Spain from Equatorial Guinea was 157	
diagnosed with MDR-TB (resistant to rifampicin, isoniazid, ethambutol, and 158	
pyrazinamide) in October 2014 in our institution. Her MTB isolate was analyzed 159	
using MIRU-VNTR, and the pattern (244214232324115153522722) was identical to 160	
the one, belonging to Lineage 4, described as prevalent in EG immigrants in Spain 161	
[11].  162	
The isolate was analyzed by whole genome sequencing, and the comparison 163	
with the reference strain (the most recent common ancestor of MTB [13,	 17])	164	
revealed 868 SNPs. These SNPs were compared with those found in a global database 165	
of representative MTB strains circulating worldwide, and, after filtering out shared 166	
SNPs, we kept 85 SNPs as potentially strain-specific for EG-MDR strain. Four of 167	
these SNPs (Table) were finally selected to be targeted in a newly designed ASO-168	
PCR (Figure 1).  169	
 170	
The specificity of our EG-MDR strain-specific ASO-PCR was tested on a 171	
selection of strains, including those from the newly diagnosed immigrant and a 172	
selection of 15 unrelated strains randomly selected from our collection (one lineage 2, 173	
one lineage 6 and the remaining lineage 4). The expected ASO-PCR patterns were 174	
obtained in all cases. 175	
 176	
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Prospective application of the ASO-PCR  177	
 178	
When the optimized EG-MDR strain-specific PCR was about to be 179	
prospectively applied on new cases diagnosed in Equatorial Guinea, we found 180	
ourselves faced with a challenging situation, namely, the absence of cultured MTB 181	
isolates resulting from the lack of capacity in laboratories in Equatorial Guinea. The 182	
only material available was the remnants from the reaction mixtures from an 183	
assessment of resistance based on GeneXpert that was simultaneously running in the 184	
country.   185	
The ASO-PCR was applied to 158 purified remnants from the GeneXpert 186	
reaction mixtures from consecutive respiratory specimens. The evaluators were blind 187	
to the GeneXpert resistance data. An interpretable result was obtained in 147 cases 188	
(93.6%) (Figure 1b). The EG-MDR strain was identified in 12 cases (8%) of all those 189	
with an ASO-PCR result. All specimens with an EG-MDR pattern corresponded to 190	
strains shown to be rifampicin resistant by GeneXpert, and 44.4% of all cases with 191	
resistance in Equatorial Guinea corresponded to infections with the EG-MDR strain.  192	
A mixed pattern including the EG-MDR and non-EG-MDR profiles was found 193	
in 1 case. When the ASO-PCR results were compared with those from GeneXpert, the 194	
11 specimens without an interpretable ASO-PCR result corresponded to specimens 195	
with low (8 specimens) or medium (3 specimens) bacterial load.  196	
MIRU-VNTR for the specimens with an ASO-PCR pattern corresponding to 197	
the EG-MDR strain was performed from the scarce amount of purified DNA that was 198	
available after applying the ASO-PCR. Given the limited material available, a 199	
complete 15-loci MIRU-VNTR pattern was obtained from 5 of the 12 specimens with 200	
a result that was consistent with the EG-MDR strain; only incomplete patterns (9-12 201	
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loci) were obtained for the remaining 7 specimens. In all cases, the allelic values 202	
coincided with those of the EG-MDR strain. As for the specimen with a mixed EG-203	
MDR/non–EG-MDR pattern by ASO-PCR, the mixed infection was confirmed as 204	
indicated by double alleles at 5 loci, with one of the mixed MIRU-VNTR profiles 205	
identical to that of the EG-MDR strain.  206	
In addition to the consecutive Equatorial Guinean specimens, the ASO-PCR 207	
was also applied to a selection of 6 Equatorial Guinean patients who had travelled to 208	
Cameroon to receive treatment for resistant TB. In these cases, the ASO-PCR was 209	
performed on the remnants received from the purified DNA used for the Genotype 210	
(Hain) test performed to confirm resistance in Cameroon. The ASO-PCR revealed 211	
that all 6 cases were infected by the EG-MDR strain, thus confirming its high 212	
prevalence among resistant cases. 213	
Second-line susceptibility patterns were obtained in a selection of 10 cases 214	
infected by the EG-MDR strain. In 1 case, we detected resistance to fluoroquinolones 215	
in addition to resistance to rifampicin and isoniazid. 216	
 217	
Retrospective application of the ASO-PCR  218	
Our objective was to evaluate whether the EG-MDR strain, which is highly 219	
prevalent in Equatorial Guinea today, or alternatively the parental strain preceding the 220	
acquisition of resistance was also present 15 years previously, when multidrug 221	
resistance was not yet a major problem in the country.  222	
The same ASO-PCR used to prospectively survey the EG-MDR in Equatorial 223	
Guinea was now applied to a collection of MTB isolates obtained 15 years ago from a 224	
population-based survey to assess resistance in Equatorial Guinea between March 225	
1999 and February 2001. We selected 93 isolates, which included 1 representative 226	
  11
isolate of 18 of the 21 clusters detected in that study using IS6110-RFLP [18],	 and the 227	
remaining orphan strains. These included the viable resistant strains from that study (9 228	
isoniazid-resistant, 2 MDR, and 2 polyresistant). 229	
An interpretable pattern was obtained from a crude boiled extract in all 93 230	
isolates (Figure 2). The EG-MDR pattern was identified in 2 cases, which 231	
corresponded to 2 of the 8 MDR cases in that study (1 new isoniazid+rifampicin–232	
resistant case and a previously treated isoniazid+rifampicin+streptomycin–resistant 233	
case). MIRU-VNTR confirmed that the pattern from the 2 cases corresponded to the 234	
EG-MDR strain.  235	
 The 2 representative isolates for the EG-MDR strain identified 15 years ago 236	
were analyzed by WGS to compare data with those from the representative strain 237	
circulating today. All 3 shared the mutations conferring resistance to rifampicin 238	
(position 761155CT; rpoB S450L) and isoniazid (position 1673425CT; inhA 239	
promoter mutation –15). One of the two historical isolates showed 2 SNPs not shared 240	
by the others (position 1472358CT, which confers resistance to streptomycin, and 241	
position 2155198GA [katG G305D]). The 2014 isolate yielded 6 SNPs not found in 242	
the historical representatives: embB (M306I), which is involved in ethambutol 243	
resistance, pcnA (X187R), which is involved in pyrazinamide resistance, and 4 244	




DISCUSSION    248	
 249	
The implementation of molecular epidemiology strategies in various countries 250	
has demonstrated the usefulness of this approach for identifying recent transmission 251	
chains and the extent to which they occur in contexts where they have been missed by 252	
standard contact-tracing analysis. TB control programs could benefit from being able 253	
to prioritize the often limited resources they assign to transmission control activities 254	
by applying them to the transmission events responsible for the highest number of 255	
secondary cases in their population. Strain-specific PCRs have been developed to 256	
track the most efficiently transmitted strains in a population [2‐5]. However, the 257	
design of strain-specific PCRs requires in-depth knowledge of the genetic 258	
composition of the strains targeted for surveillance in order to identify specific genetic 259	
features or genotypic rearrangements to be targeted. Today, WGS enables us to 260	
identify specific genetic features, namely, SNPs, in any strain, thus expanding our 261	
capacity to design strain-specific PCRs to track the most efficiently transmitted strains 262	
in a population.  263	
We recently proved the effectiveness of these novel strategies for specifically 264	
tracking strains transmitted efficiently in a population with a high proportion of 265	
immigrants [8]	 and for rapid interrogation of a retrospective collection to determine 266	
the presence of an outbreak strain [9]. Another example of the application of specific 267	
PCRs in refining the definition of an outbreak has been published elsewhere [15]. 268	
In the present study, we go one step further, by integrating these 2 challenges 269	
(prospective efficient survey and fast historical analysis) into a single problem, which 270	
is representative of the highest alert in TB from a clinical/epidemiological point of 271	
view, namely, the transmission of multidrug resistance. The application of our 272	
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strategy in this scenario enabled us to illustrate the predominance of a single MDR 273	
strain in Equatorial Guinea 15 years after its emergence. 274	
Our simple and fast test was able to identify cases infected by the prevalent 275	
EG-MDR strain, even in a challenging analytical situation, because cultured isolates 276	
were not available. Our test performed well with the remnants of GeneXpert reaction 277	
mixtures, and we observed a high percentage of interpretable results (93%), 278	
considering that remnants were stored at room temperature for several weeks before 279	
being sent to our laboratory for analysis.  280	
The potential of GeneXpert remnants as templates for molecular epidemiology 281	
analysis had not been previously tested. Our results highlight the value of the 282	
combination of cheap and easy-to-implement surveillance tests with the stabilized 283	
extracted material offered by GeneXpert, which is used worldwide, even in most low-284	
resource countries. Replicating our strategy could improve our limited knowledge of 285	
the molecular epidemiology of TB in many low-resource settings, even in those where 286	
culture facilities are not available.  287	
One interesting additional finding was the identification of a mixed infection 288	
involving an EG-MDR strain and another strain. Although data available were not 289	
sufficient to rule out the involvement of cross-transmission it illustrates the ability of 290	
the technique to identify simultaneous infections by more than one strain.  291	
One added value of our strategy was that it enabled us to integrate the 292	
prospective survey of the prevalent EG-MDR strain with parallel historical tracking of 293	
its emergence in the country. The simplicity of our design facilitated transfer of the 294	
reagents to the laboratory in Barcelona, where the isolates obtained in the first 295	
molecular epidemiology study run in Equatorial Guinea 15 years ago were stored 296	
[18]. The sensitivity of the test made it possible to analyze the stored isolates directly 297	
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from a crude boiled extract, without the need to subculture or purify DNA, thus 298	
making the test fast and inexpensive.  299	
Two cases were infected by the EG-MDR strain in the retrospective collection. 300	
During those years most cases were monoresistant to isoniazid, and only 8 cases 301	
(3.4%) were MDR [19]. One of the 2 cases was newly diagnosed and the other 302	
previously treated.  303	
Our findings provide a snapshot of 2 relevant moments in the history of 304	
multidrug resistance in Equatorial Guinea. The first was the emergence of an MDR 305	
strain, most likely in a treated case 15 years ago. In the second, we see the dramatic 306	
consequences of this emergence because today, the same strain is responsible for half 307	
of all resistant cases in the country, most likely because of transmission, as indicated 308	
by the fact that the EG-MDR strain is mainly isolated from new cases (data not 309	
shown). 310	
The identification of representatives of the EG-MDR strain 15 years apart 311	
offers an extraordinary opportunity to analyze the variability acquired by an MDR 312	
strain over a long period. Surprisingly, for an MDR strain that was actively 313	
transmitted over such a long period (when compensatory mutations and additional 314	
variability are likely to be expected) [20,	 21], we observed low variability based on 315	
SNPs within the same range as that expected in a standard recent transmission chain 316	
occurring over a limited period [22]. This finding is consistent with one of the 317	
peculiarities of Equatorial Guinea: the lack of a national program to treat MDR-TB 318	
means that the EG-MDR strain has not been exposed to efficient therapeutic 319	
regimens, thus obviating the selection of variability that had likely occurred under 320	
standard anti-TB selective pressure.  321	
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It is particularly worrying that, compared with its historical ancestor, the EG-322	
MDR strain developed additional resistance within this prolonged transmission 323	
dynamic (ethambutol and pyrazinamide, 1 isolate; fluoroquinolones, 1 isolate). The 324	
acquisition of resistance to fluoroquinolones is probably due to the frequent use of 325	
ciprofloxacin in many African countries, as recently stated in a report alerting to the 326	
cross-border migration of MDR cases from Equatorial Guinea to Cameroon to receive 327	
treatment [23]. In a sample of patients who migrated to Cameroon, all members were 328	
infected by the EG-MDR strain, thus highlighting the importance of tracking the 329	
potential transmission of the EG-MDR strain in the neighboring country. The final 330	
objective of our strategy, which was based on tailoring a strain-specific PCR to 331	
address local transmission challenges, is to transfer the tests to be implemented 332	
locally. We are collaborating with Bamenda hospital in Cameroon to implement the 333	
EG-MDR–specific PCR locally and optimize rapid analysis in situ. 334	
 Our study enabled us to analyze the dramatic consequences of the emergence 335	
of a MDR strain 15 years ago that is responsible for half of the MDR cases in 336	
Equatorial Guinea today. Transmission was likely enhanced by the dramatic 337	
socioeconomic transformation of the country and the lack of a national program to 338	
treat MDR-TB. This worrying situation must be appropriately managed to minimize 339	
the impact on both neighboring countries and on host countries receiving immigrants 340	
from this area. Our novel strategy, which integrated WGS analysis and strain-specific 341	
PCRs, could facilitate surveillance and represent a model for new control programs 342	
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1. a) Amplification patterns obtained from EG-MDR strain-specific multiplex ASO-453	
PCR results for control EG-MDR and non–EG-MDR strains. The amplicons 454	
corresponding to each of the 4 targeted SNPs are indicated. b) A selection of EG-455	
MDR and non-EG-MDR strains. MW, 100-bp ladder. 456	
 457	
2. Results obtained after applying the EG-MDR strain-specific multiplex ASO-PCR 458	
to a selection of historical isolates. The isolates identified as EG-MDR or non-EG-459	
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